Table 3.

Univariate and multivariate analysis for breast cancer specific survival in ER+/HER2− breast cancer patients

		Univariate			Mutivariate
		P‐value	HR	95% CI	P‐value	HR	95% CI
FGFR1 amplification	Normal
a: normal	versus	0.92	0.90	0.048–5.09	0.74	0.65	0.026–6.02
b: Gain/amplification	Gain/amplification
FGFR1 mRNA expression
a: low	Low versus high	0.51	0.59	0.086–2.63	0.46	0.49	0.045–3.01
b: high
FGFR1 protein expression
a: low	Low versus high	0.70	1.33	0.27–5.43	0.31	2.50	0.40–14.63
b: high
Age
a: <50	<50 vs ≥50	0.93	0.93	0.21–6.34	0.77	0.59	0.022–14.32
b: ≥50
Menstrual status
a: premenopause	Pre versus post	0.83	1.19	0.27–8.13	0.69	2.09	0.10–75.83
b: postmenopause
BMI
a: <23	<23 vs ≥23	0.27	2.20	0.54–10.76	0.082	4.65	0.82–40.62
b: ≥23
Nuclear grade
a: 1	1 vs 2, 3	0.16	2.72	0.67–13.30	0.86	1.16	0.22–6.72
b: 2, 3
Tumor invasion size	≤20 mm
a: ≤20 mm	vs	0.32	2.04	0.50–9.93	0.72	1.38	0.26–10.53
b: >20 mm	>20 mm
Nodal status
a: +	+ vs −	0.032*	4.97	1.14–33.95	0.018*	9.87	1.43–201.32
b: −
Ki67
a: <15%	<15% vs ≥15%	0.14	3.91	0.67–73.92	0.42	2.37	0.33–47.96
b: ≥15%

*χ² test: P < 0.05; CI, confidence interval; ER+/HER2−, estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative; FGFR1, fibroblast growth factor receptor‐1; HR, hazard ratio.